Stocktoria
Clene Inc. CLNN
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2018-08-27
Chart by TradingView
1/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $200,000 | $342,000 | $654,000 | $473,000 | $723,000 |
| Operating income | -$23.1M | -$33.1M | -$40.5M | -$48.4M | -$50.0M |
| Net income | -$26.2M | -$39.4M | -$49.5M | -$29.9M | -$9.7M |
| Operating cash flow | -$18.5M | -$21.3M | -$30.2M | -$39.0M | -$34.6M |
| Free cash flow | -$18.6M | -$21.3M | -$30.5M | -$44.2M | -$36.0M |
| Total assets | $18.1M | $27.3M | $52.3M | $44.5M | $63.1M |
| Total liabilities | $35.7M | $36.2M | $39.0M | $41.3M | $50.5M |
| Shareholders' equity | -$17.6M | -$8.9M | $13.4M | $3.2M | $12.6M |
| Ratios | |||||
| Operating margin | -11541.5% | -9676.3% | -6198.8% | -10234.5% | -6912.6% |
| Net margin | -13086.5% | -11520.5% | -7569.4% | -6325.2% | -1347.2% |
| FCF margin | -9292.5% | -6240.1% | -4663.8% | -9342.5% | -4973.2% |
| Return on assets | -144.4% | -144.1% | -94.6% | -67.2% | -15.4% |
| Return on equity | 148.8% | 444.8% | -369.7% | -924.3% | -77.3% |
| Debt / equity | -1.01× | — | — | — | — |
| Current ratio | 0.83 | 1.57 | 1.53 | 2.11 | 9.06 |
| Revenue growth | -41.5% | -47.7% | 38.3% | -34.6% | 251.0% |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001822791 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.